3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
28
Leukemia, Myeloid, Acute
9
Neoplasms
7
Lymphoma, Non-Hodgkin
7
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Immunoglobulin Light-chain Amyloidosis
5
Leukemia, Lymphocytic, Chronic, B-Cell
4
Myelodysplastic Syndromes
3
Amyloidosis
3
Prostatic Neoplasms
2
Neoplasms, Plasma Cell
2
Hematologic Neoplasms
2
Breast Neoplasms
2
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Dexamethasone
10
fludarabine phosphate
9
Melphalan
9
fludarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
7
Cyclophosphamide
7
Mycophenolic Acid
6
Bortezomib
6
Tacrolimus
5
Calcium Dobesilate
4
filanesib
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
daratumumab
3
carfilzomib
3
auricularum
3
Stem Cell Transplantation
3
Sirolimus
3
Filgrastim
3
liposomal doxorubicin
2
ixazomib
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Cytarabine
2
Cyclosporine
2
Carmustine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Plasma Cell
×
venetoclax
×
Plasma cell
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available